Drug Profile
AFX 9901
Alternative Names: AFX-9901Latest Information Update: 30 Mar 2021
Price :
$50
*
At a glance
- Originator Afecta Pharmaceuticals
- Class Antihaemorrhagics; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemorrhage
- Discontinued Cancer
Most Recent Events
- 30 Mar 2021 Discontinued - Clinical-Phase-Unknown for Cancer in USA (unspecified route) before March 2021 (Afecta Pharmaceuticals pipeline, March 2021)
- 26 Mar 2021 Preclinical trials in Haemorrhage in USA (unspecified route) before March 2021 (Afecta Pharmaceuticals pipeline, March 2021)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in USA